^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SLC22A2 (Solute Carrier Family 22 Member 2)

    i
    Other names: SLC22A2, Solute Carrier Family 22 Member 2, OCT2, Organic Cation Transporter 2, Solute Carrier Family 22 (Organic Cation Transporter), Member 2, HOCT2
    Associations

    News

    Trials
    3ms
    Alzheimer's disease multi-ancestry genome-wide interaction and stratified study with smoking. (PubMed, Alzheimers Dement)
    Among smokers only, a novel chromosome 12 single nucleotide polymorphism (SNP) near ANKS1B was associated with Alzheimer's disease. Evidence came from European and African ancestry cohorts. RNA-sequencing analyses implicated the top SNP as causal via ANKS1B expression in oligodendrocytes. A genome-wide African ancestry-specific significant SNP-smoking interaction was observed on chromosome 6 in SLC22A23.
    Journal
    |
    APP (Amyloid Beta Precursor Protein) • APAF1 (Apoptotic peptidase activating factor 1) • SLC22A2 (Solute Carrier Family 22 Member 2)
    4ms
    Deciphering the structural impact of norepinephrine analog radiopharmaceuticals on organic cation transporter affinity. (PubMed, Biomed Pharmacother)
    This study highlights the critical influence of the compounds' chemical structure on NET and OCT affinities. Structural modifications that reduce OCT-mediated uptake while maintaining high NET affinity could improve the specificity and theranostic potential of NET-targeting ligands. These findings provide insights for designing next-generation radiotracers with enhanced selectivity and clinical utility.
    Journal
    |
    SLC22A1 (Solute Carrier Family 22 Member 1) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    Azedra (iobenguane I 131)
    5ms
    Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice. (PubMed, Eur J Pharm Sci)
    Among the tested PPIs (lansoprazole, omeprazole, rabeprazole, and esomeprazole), the inhibitory effect of esomeprazole on hOCT2-mediated L-OHP transport was greater than those of other PPIs. Thus, to the best of our knowledge, our study demonstrates for the first time that concomitant esomeprazole prevents OIPN, at least in part, by inhibiting OCT2-mediated L-OHP transport into the DRG, thus decreasing L-OHP accumulation in the DRG. These findings provide important information for the establishment of novel protective approaches to minimize OIPN.
    Preclinical • Journal
    |
    SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    oxaliplatin • omeprazole
    5ms
    CXCR 4, PAX5, and OCT2 Immunohistochemical Expressions in Diffuse Large B-Cell Lymphoma and Their Relationship with XIST/miR-34/PAX5 Axis. (PubMed, J Interferon Cytokine Res)
    In addition, the XIST/miR-34/PAX5 axis may serve as a potential diagnostic marker in DLBCL. Moreover, CXCR4 and XIST/miR-34/PAX5 expressions may be potential prognostic markers in DLBCL.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • PAX5 (Paired Box 5) • MIR34A (MicroRNA 34a-5p) • SLC22A2 (Solute Carrier Family 22 Member 2) • XIST (X Inactive Specific Transcript)
    5ms
    Prognostic associations of PFAS in ovarian cancer: Insights from exploratory analysis. (PubMed, Ecotoxicol Environ Saf)
    In this exploratory study, PFAS-derived risk scores showed potential for predicting OC prognosis and might offer insights relevant to clinical treatment strategies, pointing to the potential prognostic role of PFAS in OC.
    Journal
    |
    SLC22A2 (Solute Carrier Family 22 Member 2)
    6ms
    Diagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens. (PubMed, Ann Diagn Pathol)
    In conclusion, CD30-negative cHL diagnosed on limited biopsy material tends to affect younger male patients and retains typical morphological and immunophenotypic hallmarks of cHL. A thorough diagnostic approach incorporating multi-clone CD30 IHC and repeat sampling when necessary is crucial to avoid misdiagnosis in these diagnostically ambiguous cases.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • IRF4 (Interferon regulatory factor 4) • ATF3 (Activating Transcription Factor 3) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    CD20 positive • TNFRSF8 expression
    8ms
    Lansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico, in vitro, and in vivo analyses. (PubMed, Biomed Pharmacother)
    These findings suggest that the concomitant administration of lansoprazole ameliorates OIPN by inhibiting OCT2-mediated L-OHP uptake in the mouse DRG. Our findings provide important insights for the establishment of novel protective approaches against OIPN.
    Preclinical • Journal
    |
    SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    oxaliplatin
    8ms
    EPHX1 and ERCC2 polymorphisms are associated with cisplatin-induced nephrotoxicity and prognosis in Thai cancer patients. (PubMed, PLoS One)
    Our results reveal an association between EPHX1 rs1051740 and AKD, and confirms the previously reported associations between ERCC2 SNPs and OS. These findings may help in predicting CIN in Thai cancer patients.
    Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • EPHX1 (Epoxide Hydrolase 1) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    cisplatin
    10ms
    Chronic liver injury decreases levels of cerebral carnitine and acetylcarnitine in rats partly due to the downregulation of organic cation transporters OCT1/2 and OCTN2 at the blood-brain barrier. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: This study revealed that the deficiency of brain carnitine and acetylcarnitine in thioacetamide-induced chronic liver injury rats is mainly attributed to the downregulation of organic cation transporter 1/2 and organic cation/carnitine transporter 2 expressions at the blood-brain barrier. The increased circulating levels of chenodeoxycholic acid and 17β-estradiol play a significant role in the downregulation of organic cation transporter 1/2 and organic cation/carnitine transporter 2 expression in chronic liver injury.
    Preclinical • Journal
    |
    SLC22A1 (Solute Carrier Family 22 Member 1) • SLC22A2 (Solute Carrier Family 22 Member 2)
    11ms
    Pharmacogenomics in pediatric oncology patients with solid tumors related to chemotherapy-induced toxicity: a systematic review. (PubMed, Crit Rev Oncol Hematol)
    For methotrexate, the genes ABCC2, MTHFR, and SXR were associated with myelosuppression and hepatotoxicity...This review highlights the complexity and variability of pharmacogenomic associations with chemotherapy-induced toxicities in pediatric oncology. While certain genetic variants show associations with specific toxicities, larger multinational/center studies are needed to strengthen the associations and improve clinical guidelines.
    Review • Journal
    |
    ERCC2 (Excision repair cross-complementation group 2) • GSTP1 (Glutathione S-transferase pi 1) • MTHFR (Methylenetetrahydrofolate Reductase) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ABCB4 (ATP Binding Cassette Subfamily B Member 4) • ABCC3 (ATP Binding Cassette Subfamily C Member 3) • GSTM1 (Glutathione S-transferase mu 1) • HAS3 (Hyaluronan Synthase 3) • RARG (Retinoic Acid Receptor Gamma) • GSTT1 (Glutathione S-transferase theta 1) • SLC22A2 (Solute Carrier Family 22 Member 2) • SLC28A3 (Solute Carrier Family 28 Member 3) • CELF4 (CUGBP Elav-Like Family Member 4) • COMT (Catechol-O-Methyltransferase)
    |
    methotrexate
    12ms
    Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Our study confirmed that carvedilol and cimetidine exert protective effects against Cis-AKI by inhibiting OCT2, without altering the anti-tumor effects of cisplatin.
    Journal
    |
    SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    cisplatin
    12ms
    Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia. (PubMed, Int J Hematol)
    This study revealed that bosutinib-induced elevation of serum creatinine, which was more pronounced in patients with the SLC22A2 808G/G genotype, does not indicate chronic kidney disease, but rather is simply a laboratory abnormality. If bosutinib-induced chronic kidney disease is suspected, renal function should be assessed by urinalysis and cystatin C levels to differentiate from simple elevation of serum creatinine.
    Journal
    |
    SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    bosutinib